Remove Disease Remove Image Interpretation Remove Imaging Remove Radiation Oncology
article thumbnail

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. This includes MIMneuro , which offers quantification solutions for dopamine transporter imaging and amyloid imaging.

article thumbnail

Meet the Minnies 2024 semifinal candidates

AuntMinnie

The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. Image from Martin W. Image from Denis Le Bihan, PhD, of the NeuroSpin research facility, et al. Image from Richard Carson, PhD, of Yale University, et al.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Gauden , D.Phil., Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil., Kuo, MD, Ph.D.,

article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Recently approved by the U.S. on behalf of Gary A.